How many drugs treat Actinic keratosis?

Drug Landscape tracks 10 marketed treatments for Actinic keratosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/actinic-keratosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Actinic keratosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Actinic keratosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Actinic keratosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Klisyri	TIRBANIBULIN	Almirall	Microtubule Inhibitor [EPC]	Tyrosine-protein kinase Lyn	2020-01-01
Picato	INGENOL MEBUTATE	Leo Labs		Protein kinase C alpha type, Protein kinase C epsilon type, Protein kinase C gamma type	2012-01-01
Levulan	AMINOLEVULINIC ACID	Sun Pharma	Optical Imaging Agent		1999-01-01
Aldara	IMIQUIMOD	Bausch Health	imiquimod	7,8-dihydro-8-oxoguanine triphosphatase	1997-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Carac	5-fu	Spectrum Pharms	Nucleoside Metabolic Inhibitor	Aromatase	1962-01-01
Carac	fluorouracil	Extrovis	Nucleoside Metabolic Inhibitor [EPC]	Aromatase	1962-01-01
Ameluz	Ameluz	Sherrif Ibrahim
Gliolan	Gliolan	Abramson Cancer Center at Penn Medicine

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Actinic keratosis
Abramson Cancer Center at Penn Medicine · 1 drug in Actinic keratosis
Almirall · 1 drug in Actinic keratosis
Bausch Health · 1 drug in Actinic keratosis
Extrovis · 1 drug in Actinic keratosis
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Actinic keratosis
LEO Pharma · 1 drug in Actinic keratosis
Leo Labs · 1 drug in Actinic keratosis
Pfizer · 1 drug in Actinic keratosis
Sherrif Ibrahim · 1 drug in Actinic keratosis
Spectrum Pharms · 1 drug in Actinic keratosis
Sun Pharma · 1 drug in Actinic keratosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Actinic keratosis:

Cite this brief

Drug Landscape (2026). Actinic keratosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/actinic-keratosis. Accessed 2026-06-10.

Actinic keratosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing